Clinical trial
An Open Label, Multi-Center Safety and Tolerance Study of EP2101 Peptide Vaccine in Patients With Stage III Colon Cancer
NCT00054912 is registered in ClinicalTrials.gov with Epimmune as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open Label, Multi-Center Safety and Tolerance Study of EP2101 Peptide Vaccine in Patients With Stage III Colon Cancer
- Lead sponsor
- Epimmune
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- February 28, 2003
- Completion date
- Not reported
- Enrollment
- 18
- Sites
- 9
Conditions
As the registry lists them; a condition with its own page is linked.